Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOX1 | Q06278 | 1/20 | 0.78 |
| ▸ | RAD52 | P43351 | 7/20 | 0.69 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.65 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | POLR1A | O95602 | 2/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369424 | 1.00 | AOX1 (0.78) | AOX1RAD52UHRF1SMARCA2HDAC1 | |
| Hydrochloric Acid SCHEMBL29608361 | 0.99 | AOX1 (0.77) | AOX1RAD52UHRF1SMARCA2HDAC1 | |
| Hydrochloric Acid SCHEMBL4888175 | 0.99 | AOX1 (0.77) | AOX1RAD52UHRF1SMARCA2HDAC1 | |
| Hydrochloric Acid SCHEMBL5953779 | 0.97 | AOX1 (0.75) | AOX1RAD52UHRF1SMARCA2HDAC1 | |
| SCHEMBL8711841 | 0.94 | AOX1 (0.71) | AOX1RAD52UHRF1SMARCA2HDAC1 | |
| SCHEMBL7023521 | 0.88 | AOX1 (0.69) | AOX1RAD52UHRF1SMARCA2HDAC1 | |
| SCHEMBL7032809 | 0.88 | AOX1 (0.69) | AOX1RAD52UHRF1SMARCA2HDAC1 | |
| SCHEMBL2447168 | 0.88 | KDM4E (0.69) | AOX1RAD52UHRF1SMARCA2HDAC1 | |
| SCHEMBL7566347 | 0.88 | HDAC1 (0.67) | AOX1RAD52UHRF1SMARCA2HDAC1 | |
| SCHEMBL7024435 | 0.87 | AOX1 (0.74) | AOX1RAD52UHRF1SMARCA2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2684 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2026-01-08 | — | — | US | claimed |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | BIO THERA SOLUTIONS LTD (CN) | 2025-12-18 | — | — | US | claimed |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-21 | — | — | US | claimed |
| US-20250249114-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-07 | — | — | US | claimed |
| EP-4556027-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2025-05-21 | — | — | EP | claimed |
| EP-4545099-A1 | METHOD FOR TREATING SOLID TUMOR | Bio-Thera Solutions, Ltd. (CN) | 2025-04-30 | — | — | EP | claimed |
| EP-4538291-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2025-04-16 | — | — | EP | claimed |
| EP-4534105-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2025-04-09 | — | — | EP | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| EP-0642343-B1 | Acridine carboxamides for the treatment of cancer | XENOVA LTD (GB) | 2000-08-30 | — | — | EP | claimed |
| US-6111109-A | CYCLIZING A 2-(2-ALKYLOXYCARBONYLPHENYL)AMINO-)BENZALDEHYDE BY TREATING WITH A BORON TRIFLUORIDE; NEUTRALIZATION OF THE FORMED SALT; AMIDATION WITH AN 2-N,N-DIALKYLAMINOETHYLAMINE;ANTITUMOR AND -CARCINOGENIC | XENOVA LIMITED (GB) | 2000-08-29 | — | — | US | claimed |
| EP-0934277-A1 | PROCESS FOR THE PREPARATION OF N- 2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE | XENOVA LIMITED (GB) | 1999-08-11 | — | — | EP | claimed |
| US-5891886-A | PREVENTION DRUG RESISTANCE; ADMINISTERING N-(2-(DIMETHYLAMINO)ETHYL)ACRIDINE-4-CARBOXAMIDE | XENOVA LIMITED (GB) | 1999-04-06 | — | — | US | claimed |
| WO-1998017649-A1 | PROCESS FOR THE PREPARATION OF N-[2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE | XENOVA LIMITED (GB) | 1998-04-30 | — | — | WO | claimed |
| US-5696131-A | ADMINISTERING N-(2-(DIMETHYLAMINO)ETHYL)ACRIDINE-4-CARBOXAMIDE WITH OTHER ANTICANCER DRUGS IN A DIVIDED-DOSE SCHEDULE | XENOVA LIMITED (GB) | 1997-12-09 | — | — | US | claimed |
| EP-0642343-A1 | TREATMENT OF CANCERS | XENOVA LIMITED (GB) | 1995-03-15 | — | — | EP | claimed |
| WO-1993024096-A2 | USE OF N-(2-(DIMETHYLAMINO)ETHYL)ACRIDINE-4-CARBOXAMIDE AND ITS ANALOGUES FOR CANCER TREATMENT | XENOVA LIMITED (GB) | 1993-12-09 | — | — | WO | claimed |